Beaker List – Penn Edition
Top Entrepreneurial Life Science Professors @ University of Pennsylvania
BIOS: Nucleus of Life Science Innovation 🚀
JOBS
BIOS Talent: Find Jobs @ Breakout TechBio Startups — Search Jobs 🚀
Post Jobs: Add Your Startup to BIOS Talent — Post Now 🎉
Students: Join Alix Ventures Fellowship — Join Now 🧬
BIOS Contributor: Share Your Thought Leadership — Join Now🔬
CONTENT & COMMUNITY
BIOS Daily: Join 25K+ Subscribers Following TechBio — Sign Up 🔥
BIOS Insider: Premium TechBio Thought Leadership — Sign Up ✨
BIOS Commons: World’s Largest #TechBio Community — Join Now 🎉
INVEST
BIOS Angels: 1st TechBio Angel Investing Syndicate — Join Now 🌟
Alix Limited: Invest in Breakout TechBio Startups — Learn More 🧠
By:
Alix Ventures: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health
Overview
Behind every transformative technology is a team of brilliant scientists and researchers. Academic research in particular is a driving force for technological innovation. Here, we have identified a ‘Midas List’ of researchers who have pioneered highly transformative technologies that have translated to the clinic. Using venture backed startups as a primary guide along with other impact metrics such as patents, citations, and thought leadership, the following professors have demonstrated patient impact, providing significant contributions to the startup ecosystem.
The University of Pennsylvania is a world leading academic institution with top-tier programs in biomedical research, medicine and business. Particularly noteworthy is their cell immunotherapy program (coined “Cellicon Valley”), which has produced a world leading 54 inventions & 428 patents in Chimeric Antigen Receptor T-Cell (CAR-T) therapies. Find our list of the top 10 entrepreneurial professors here, which has a mix of established as well as rising stars.
Carl June
Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a leading pioneer in engineering chimeric antigen receptor immune cells for cancer, with notable accomplishments like the FDA approved Kymriah (acquired by Novartis) & co-founding TMunity.